You can Subscribe to our RSS FEED: which delivers brain tumor news and additions to the website via RSS.
Click HERE for details on RSS.
Displaying items 851 to 875 of about 5877
Next 25
06/27/2020
ERC Belgium Submits Marketing Authorization Application to European Medicines Agency (EMA) for Glioblastoma Immunotherapy, SITOIGANAP
06/25/2020
A Systematic Review of Tumor Treating Fields Therapy for High-Grade Gliomas
06/24/2020
Musella Foundation Copay Program now closed to new patients
New class of precision medicine strips cancer of its DNA defenses
DelMar Pharmaceuticals Presents Positive Interim Data on VAL-083 Demonstrating Favorable Outcomes in Both Newly- Diagnosed and Recurrent GBM at the AACR Virtual Annual Meeting II
06/22/2020
Exploiting Cancer’s Tactics to Make Cancer a Manageable Chronic Disease
06/21/2020
Brain Tumor Webinars continue tonight! Sunday 6/21/2020 7pm Eastern Time
06/18/2020
Gallagher, Colleagues Introduce Bipartisan Promising Pathways Act
06/15/2020
Karyopharm Announces Dosing of First Patient in a Phase 1/2 Study of Selinexor in Combination with Standard of Care Therapy for Patients with Newly Diagnosed or Recurrent Glioblastoma
Global Post-Marketing Safety Surveillance of Tumor Treating Fields (TTFields) in Patients With High-Grade Glioma in Clinical Practice
The Musella Foundation Awards 2 Brain Tumor Research Grants
Cancer Vaccine Plus Adoptive T-cell Therapy Placed on Fast Track
06/13/2020
Brain Tumor Webinar Series continues tonight! 6/14/2020
Global Coalition for Adaptive Research (GCAR) Selects DelMar Pharmaceuticals` VAL-083 to Participate in the GBM AGILE Pivotal Study, an Adaptive Clinical Trial Platform in Glioblastoma Multiforme
06/07/2020
Brain Tumor Webinars continue tonight!
06/05/2020
The McDowell Family Lost A Child To Cancer And Now They Are Creating a Tourist Attraction to Fund Research– So Why Are Some Of The Neighbors So Angry?
06/02/2020
Novocure Announces Launch of MyLink™ to Enable Patient-Guided, Remote Download of Optune® Usage Data
First Patient Treated in Phase 1 Clinical Trial Of Incysus Therapeutics Gamma Delta (?d) T Cell Immunotherapy for Patients With Newly Diagnosed Glioblastoma
Factors Affecting Survival in Glioblastoma: A 10-year Single-Center Experience From Saudi Arabia
06/01/2020
Phase 2a study to evaluate the safety, pharmacokinetics, and clinical activity of the PI3K / mTOR inhibitor GDC-0084 given to glioblastoma (GBM) patients with unmethylated MGMT promotor status
05/29/2020
ONC201 in previously irradiated pediatric H3 K27M-mutant glioma or newly diagnosed DIPG.
Al Musella`s ASCO Hightlights
Musella Foundation Awards Pediatric Brain Tumor Research Grant!
Musella Foundation Copay Assistance program is running low on funding
ASCO Brain Tumor Abstracts